Chikungunya virus arthritis in adult wild-type mice

Journal of Virology

Volumn 84, Issue 16, 2010, Pages 8021-8032

  Gardner, Joy ^a   Anraku, Itaru ^a   Le, Thuy T ^a   Larcher, Thibaut ^b   Major, Lee ^a   Roques, Pierre ^c   Schroder, Wayne A ^a   Higgs, Stephen ^d   Suhrbier, Andreas ^a,e  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b INRA UMR 703   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d University of Texas Medical Branch School of Medicine   (United States)

^e GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2C; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CHIKUNGUNYA ALPHAVIRUS; FEMALE; MACROPHAGE; MONOCYTE; MOUSE; MYOSITIS; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHEUMATIC DISEASE; ROSS RIVER ALPHA VIRUS; TENOSYNOVITIS; VIREMIA; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ALPHAVIRUS INFECTIONS; ANIMALS; ARTHRITIS; CHIKUNGUNYA VIRUS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FOOT; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROSCOPY; MONOCYTES; ROSS RIVER VIRUS; VACCINES, INACTIVATED; VIRAL LOAD; VIRAL VACCINES; VIREMIA;

ALPHAVIRUS; CHIKUNGUNYA VIRUS; MUS; ROSS RIVER VIRUS;

EID: 77955008245     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02603-09     Document Type: Article

References (89)

1. Aaskov, J., L. Williams, and S. Yu. 1997. A candidate Ross River virus vaccine: preclinical evaluation. Vaccine 15:1396-1404.
2. Akahata, W., Z. Y. Yang, H. Andersen, S. Sun, H. A. Holdaway, W. P. Kong, M. G. Lewis, S. Higgs, M. G. Rossmann, S. Rao, and G. J. Nabel. 2010. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16:334-338.
3. Alsharifi, M., M. Lobigs, M. M. Simon, A. Kersten, K. Muller, A. Koskinen, E. Lee, and A. Mullbacher. 2006. NK cell-mediated immunopathology during an acute viral infection of the CNS. Eur. J. Immunol. 36:887-896.
4. Anraku, I., V. V. Mokhonov, P. Rattanasena, E. I. Mokhonova, J. Leung, G. Pijlman, A. Cara, W. A. Schroder, A. A. Khromykh, and A. Suhrbier. 2008. Kunjin replicon-based simian immunodeficiency virus gag vaccines. Vaccine 26:3268-3276.
5. Antalis, T. M., M. La Linn, K. Donnan, L. Mateo, J. Gardner, J. L. Dickinson, K. Buttigieg, and A. Suhrbier. 1998. The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J. Exp. Med. 187:1799-1811.
6. Brighton, S. W., O. W. Prozesky, and A. L. de la Harpe. 1983. Chikungunya virus infection. A retrospective study of 107 cases. S. Afr. Med. J. 63:313-315.
7. Brown, F. 2001. Inactivation of viruses by aziridines. Vaccine 20:322-327.
8. Charrel, R. N., X. de Lamballerie, and D. Raoult. 2007. Chikungunya outbreaks - the globalization of vectorborne diseases. N. Engl. J. Med. 356:769-771.
9. Couderc, T., F. Chretien, C. Schilte, O. Disson, M. Brigitte, F. Guivel-Benhassine, Y. Touret, G. Barau, N. Cayet, I. Schuffenecker, P. Despres, F. Arenzana-Seisdedos, A. Michault, M. L. Albert, and M. Lecuit. 2008. A mouse model for Chikungunya: young age and inefficient type-i interferon signaling are risk factors for severe disease. PLoS Pathog. 4:e29.
10. Couderc, T., N. Khandoudi, M. Grandadam, C. Visse, N. Gangneux, S. Bagot, J. F. Prost, and M. Lecuit. 2009. Prophylaxis and therapy for Chikungunya virus infection. J. Infect. Dis. 200:516-523.
11. Dalpke, A., K. Heeg, H. Bartz, and A. Baetz. 2008. Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 213:225-235.
12. Donaghy, H., L. Bosnjak, A. N. Harman, V. Marsden, S. K. Tyring, T. C. Meng, and A. L. Cunningham. 2009. Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J. Virol. 83:1952-1961.
13. Dubrulle, M., L. Mousson, S. Moutailler, M. Vazeille, and A. B. Failloux. 2009. Chikungunya virus and Aedes mosquitoes: saliva is infectious as soon as two days after oral infection. PLoS One 4:e5895.
14. Economopoulou, A., M. Dominguez, B. Helynck, D. Sissoko, O. Wichmann, P. Quenel, P. Germonneau, and I. Quatresous. 2009. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Reunion. Epidemiol. Infect. 137:534-541.
15. Edelman, R., C. O. Tacket, S. S. Wasserman, S. A. Bodison, J. G. Perry, and J. A. Mangiafico. 2000. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62:681-685.
16. Fields, B. N., D. M. Knipe, and P. M. Howley. 1996. Alphaviruses, 3rd ed., vol. 1. Lippincott-Raven, Philadelphia, PA.
17. Fink, K., C. Ng, C. Nkenfou, S. G. Vasudevan, N. van Rooijen, and W. Schul. 2009. Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur. J. Immunol. 39:2809-2821.
18. Fraser, J. R., A. L. Cunningham, B. J. Clarris, J. G. Aaskov, and R. Leach. 1981. Cytology of synovial effusions in epidemic polyarthritis. Aust. N. Z. J. Med. 11:168-173.
19. Furtado, G. C., B. Pina, F. Tacke, S. Gaupp, N. van Rooijen, T. M. Moran, G. J. Randolph, R. M. Ransohoff, S. W. Chensue, C. S. Raine, and S. A. Lira. 2006. A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells. J. Immunol. 177:6871-6879.
20. Gardner, D. L., P. N. Skelton-Stroud, and R. J. Fitzmaurice. 1991. Acute muramyl dipeptide-induced arthritis in the baboon Papio cynocephalus. Z. Rheumatol. 50:86-92. (In German.)
21. Glasgow, L. A. 1970. Transfer of interferon-producing macrophages: new approach to viral chemotherapy. Science 170:854-856.
22. Griffin, D., B. Levine, W. Tyor, S. Ubol, and P. Despres. 1997. The role of antibody in recovery from alphavirus encephalitis. Immunol. Rev. 159:155-161.
23. Gulbahar, M. Y., W. C. Davis, H. Yuksel, and M. Cabalar. 2006. Immunohistochemical evaluation of inflammatory infiltrate in the skin and lung of lambs naturally infected with sheeppox virus. Vet. Pathol. 43:67-75.
24. Harley, D., A. Sleigh, and S. Ritchie. 2001. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin. Microbiol. Rev. 14:909-932.
25. Hazelton, R. A., C. Hughes, and J. G. Aaskov. 1985. The inflammatory response in the synovium of a patient with Ross River arbovirus infection. Aust. N. Z. J. Med. 15:336-339.
26. Hensley, S. E., A. S. Cun, W. Giles-Davis, Y. Li, Z. Xiang, M. O. Lasaro, B. R. Williams, R. H. Silverman, and H. C. Ertl. 2007. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol. Ther. 15:393-403.
27. Johnson, B. J., T. T. T. Le, C. A. Dobbin, T. Banovic, C. B. Howard, F. de Maria Leon Flores, D. Vanags, D. J. Naylor, G. R. Hill, and A. Suhrbier. 2005. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J. Biol. Chem. 280:4037-4047.
28. Kennedy, A. C., J. Fleming, and L. Solomon. 1980. Chikungunya viral arthropathy: a clinical description. J. Rheumatol. 7:231-236.
29. Kistner, O., N. Barrett, A. Bruhmann, M. Reiter, W. Mundt, H. Savidis- Dacho, S. Schober-Bendixen, F. Dorner, and J. Aaskov. 2007. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 25:4845-4852.
30. Koga, T., K. Kakimoto, T. Hirofuji, S. Kotani, H. Ohkuni, K. Watanabe, N. Okada, H. Okada, A. Sumiyoshi, and K. Saisho. 1985. Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria. Infect. Immun. 50:27-34.
31. Kumar, N. P., R. Joseph, T. Kamaraj, and P. Jambulingam. 2008. A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. J. Gen. Virol. 89:1945-1948.
32. Labadie, K., T. Larcher, C. Joubert, A. Mannioui, B. Delache, P. Brochard, L. Guigand, L. Dubreil, P. Lebon, B. Verrier, X. de Lamballerie, A. Suhrbier, Y. Cherel, R. Le Grand, and P. Roques. 2010. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J. Clin. Invest. 120:894-906.
33. La Linn, M., A. J. Bellett, P. G. Parsons, and A. Suhrbier. 1995. Complete removal of mycoplasma from viral preparations using solvent extraction. J. Virol. Methods 52:51-54.
34. La Linn, M., J. A. Eble, C. Lubken, R. W. Slade, J. Heino, J. Davies, and A. Suhrbier. 2005. An arthritogenic alphavirus uses the alpha1beta1 integrin collagen receptor. Virology 336:229-239.
35. Larrieu, S., N. Pouderoux, T. Pistone, L. Filleul, M. C. Receveur, D. Sissoko, K. Ezzedine, and D. Malvy. 2010. Factors associated with persistence of arthralgia among chikungunya virus-infected travellers: report of 42 French cases. J. Clin. Virol. 47:85-88.
36. Latif, Z., D. Gates, C. J. Wust, and A. Brown. 1979. Cross protection among togaviruses in nude mice and littermates. J. Gen. Virol. 45:89-98.
37. Lidbury, B. A., N. E. Rulli, A. Suhrbier, P. N. Smith, S. R. McColl, A. L. Cunningham, A. Tarkowski, N. van Rooijen, R. J. Fraser, and S. Mahalingam. 2008. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J. Infect. Dis. 197:1585-1593.
38. Linn, M. L., L. Mateo, J. Gardner, and A. Suhrbier. 1998. Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages. J. Virol. 72:5146-5153.
39. Liu, W. J., X. J. Wang, D. C. Clark, M. Lobigs, R. A. Hall, and A. A. Khromykh. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J. Virol. 80:2396-2404.
40. Lukaszewski, R. A., and T. J. Brooks. 2000. Pegylated alpha interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J. Virol. 74:5006-5015.
41. Mahalingam, S., and B. A. Lidbury. 2002. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc. Natl. Acad. Sci. U. S. A. 99:13819-13824.
42. Mavalankar, D., P. Shastri, T. Bandyopadhyay, J. Parmar, and K. V. Ramani. 2008. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg. Infect. Dis. 14:412-415.
43. Mazzoran, L., F. Zorat, L. Chemello, L. S. Croce, I. Rigato, L. Cavalletto, E. Bernardinello, C. Tiribelli, A. Alberti, and G. Pozzato. 2001. Human leucocyte interferon-alpha in the treatment of chronic hepatitis C. Dig. Liver Dis. 33:347-352.
44. Minke, J. M., J. C. Audonnet, and L. Fischer. 2004. Equine viral vaccines: the past, present and future. Vet. Res. 35:425-443.
45. Mogal, A., and S. A. Abdulkadir. 2006. Effects of histone deacetylase inhibitor (HDACi); trichostatin-A (TSA) on the expression of housekeeping genes. Mol. Cell. Probes 20:81-86.
46. Morrison, T. E., A. C. Whitmore, R. S. Shabman, B. A. Lidbury, S. Mahalingam, and M. T. Heise. 2006. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J. Virol. 80:737-749.
47. Muthumani, K., K. M. Lankaraman, D. J. Laddy, S. G. Sundaram, C. W. Chung, E. Sako, L. Wu, A. Khan, N. Sardesai, J. J. Kim, P. Vijayachari, and D. B. Weiner. 2008. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 26:5128-5134.
48. Mylonas, A. D., A. M. Brown, T. L. Carthew, B. McGrath, D. M. Purdie, N. Pandeya, P. C. Vecchio, L. G. Collins, I. D. Gardner, F. J. de Looze, E. J. Reymond, and A. Suhrbier. 2002. Natural history of Ross River virus-induced epidemic polyarthritis. Med. J. Aust. 177:356-360.
49. Nagata, S. 2008. Rheumatoid polyarthritis caused by a defect in DNA degradation. Cytok. Growth Factor Rev. 19:295-302.
50. Ng, K. W., A. Chow, M. K. Win, F. Dimatatac, H. Y. Neo, D. C. Lye, and Y. S. Leo. 2009. Clinical features and epidemiology of chikungunya infection in Singapore. Singapore Med. J. 50:785-790.
51. Ng, L. F., A. Chow, Y. J. Sun, D. J. Kwek, P. L. Lim, F. Dimatatac, L. C. Ng, E. E. Ooi, K. H. Choo, Z. Her, P. Kourilsky, and Y. S. Leo. 2009. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One 4:e4261.
52. Njenga, M. K., L. Nderitu, J. P. Ledermann, A. Ndirangu, C. H. Logue, C. H. Kelly, R. Sang, K. Sergon, R. Breiman, and A. M. Powers. 2008. Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa. J. Gen. Virol. 89:2754-2760.
53. O'Brien, L., S. Perkins, A. Williams, L. Eastaugh, A. Phelps, J. Wu, and R. Phillpotts. 2009. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J. Gen. Virol. 90:874-882.
54. Ozden, S., M. Huerre, J. P. Riviere, L. L. Coffey, P. V. Afonso, V. Mouly, J. de Monredon, J. C. Roger, M. El Amrani, J. L. Yvin, M. C. Jaffar, M. P. Frenkiel, M. Sourisseau, O. Schwartz, G. Butler-Browne, P. Despres, A. Gessain, and P. E. Ceccaldi. 2007. Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One 2:e527.
55. Parola, P., X. de Lamballerie, J. Jourdan, C. Rovery, V. Vaillant, P. Minodier, P. Brouqui, A. Flahault, D. Raoult, and R. N. Charrel. 2006. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg. Infect. Dis. 12:1493-1499.
56. Pialoux, G., B. A. Gauzere, S. Jaureguiberry, and M. Strobel. 2007. Chikungunya, an epidemic arbovirosis. Lancet Infect. Dis. 7:319-327.
57. Pyke, A. T., D. A. Phillips, T. F. Chuan, and G. A. Smith. 2004. Sucrose density gradient centrifugation and cross-flow filtration methods for the production of arbovirus antigens inactivated by binary ethylenimine. BMC Microbiol. 4:3.
58. Repik, P. M., J. M. Dalrymple, W. E. Brandt, J. M. McCown, and P. K. Russell. 1983. RNA fingerprinting as a method for distinguishing dengue 1 virus strains. Am. J. Trop. Med. Hyg. 32:577-589.
59. Rulli, N. E., A. Guglielmotti, G. Mangano, M. S. Rolph, C. Apicella, A. Zaid, A. Suhrbier, and S. Mahalingam. 2009. Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheum. 60:2513-2523.
60. Ryman, K. D., and W. B. Klimstra. 2008. Host responses to alphavirus infection. Immunol. Rev. 225:27-45.
61. Schneider, B. S., and S. Higgs. 2008. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans. R. Soc. Trop. Med. Hyg. 102:400-408.
62. Schuffenecker, I., I. Iteman, A. Michault, S. Murri, L. Frangeul, M. C. Vaney, R. Lavenir, N. Pardigon, J. M. Reynes, F. Pettinelli, L. Biscornet, L. Diancourt, S. Michel, S. Duquerroy, G. Guigon, M. P. Frenkiel, A. C. Brehin, N. Cubito, P. Despres, F. Kunst, F. A. Rey, H. Zeller, and S. Brisse. 2006. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3:e263.
63. Selmi, C., A. Lleo, M. Zuin, M. Podda, L. Rossaro, and M. E. Gershwin. 2006. Interferon alpha and its contribution to autoimmunity. Curr. Opin. Invest. Drugs 7:451-456.
64. Simmons, J. D., L. J. White, T. E. Morrison, S. A. Montgomery, A. C. Whitmore, R. E. Johnston, and M. T. Heise. 2009. Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff. J. Virol. 83:10571-10581.
65. Soden, M., H. Vasudevan, B. Roberts, R. Coelen, G. Hamlin, S. Vasudevan, and J. La Brooy. 2000. Detection of viral ribonucleic acid and histologic analysis of inflamed synovium in Ross River virus infection. Arthritis Rheum. 43:365-369.
66. Sourisseau, M., C. Schilte, N. Casartelli, C. Trouillet, F. Guivel-Benhassine, D. Rudnicka, N. Sol-Foulon, K. Le Roux, M. C. Prevost, H. Fsihi, M. P. Frenkiel, F. Blanchet, P. V. Afonso, P. E. Ceccaldi, S. Ozden, A. Gessain, I. Schuffenecker, B. Verhasselt, A. Zamborlini, A. Saib, F. A. Rey, F. Arenzana-Seisdedos, P. Despres, A. Michault, M. L. Albert, and O. Schwartz. 2007. Characterization of reemerging chikungunya virus. PLoS Pathog. 3:e89.
67. Stittelaar, K. J., H. W. Vos, G. van Amerongen, G. F. Kersten, A. D. Osterhaus, and R. L. de Swart. 2002. Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates. Vaccine 21:155-157.
68. Stock, I. 2009. Chikungunya fever - expanded distribution of a re-emerging tropical infectious disease. Med. Monatsschr. Pharm. 32:17-26. (In German.)
69. Suhrbier, A., and M. La Linn. 2004. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr. Opin. Rheumatol. 16:374-379.
70. Suhrbier, A., and M. La Linn. 2003. Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol. 24:165-168.
71. Suhrbier, A., and S. Mahalingam. 2009. The immunobiology of viral arthritides. Pharmacol. Ther. 124:301-308.
72. Suryawanshi, S. D., A. H. Dube, R. K. Khadse, S. V. Jalgaonkar, P. S. Sathe, S. D. Zawar, and M. P. Holay. 2009. Clinical profile of chikungunya fever in patients in a tertiary care centre in Maharashtra, India. Indian J. Med. Res. 129:438-441.
73. Tiwari, M., M. Parida, S. R. Santhosh, M. Khan, P. K. Dash, and P. V. Rao. 2009. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27:2513-2522.
74. Townson, H., and M. B. Nathan. 2008. Resurgence of chikungunya. Trans. R. Soc. Trop. Med. Hyg. 102:308-309.
75. Tsetsarkin, K., S. Higgs, C. E. McGee, X. De Lamballerie, R. N. Charrel, and D. L. Vanlandingham. 2006. Infectious clones of Chikungunya virus (La Reunion isolate) for vector competence studies. Vector Borne Zoonotic Dis. 6:325-337.
76. Tsetsarkin, K. A., D. L. Vanlandingham, C. E. McGee, and S. Higgs. 2007. A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 3:e201.
77. Tudor, D., S. Riffault, C. Carrat, F. Lefevre, M. Bernoin, and B. Charley. 2001. Type I IFN modulates the immune response induced by DNA vaccination to pseudorabies virus glycoprotein C. Virology 286:197-205.
78. Valamparampil, J. J., S. Chirakkarot, S. Letha, C. Jayakumar, and K. M. Gopinathan. 2009. Clinical profile of Chikungunya in infants. Indian J. Pediatr. 76:151-155.
79. van Rooijen, N., and E. van Kesteren-Hendrikx. 2002. Clodronate liposomes: perspectives in research and therapeutics. J. Liposome Res. 12:81-94.
80. Vazeille, M., S. Moutailler, D. Coudrier, C. Rousseaux, H. Khun, M. Huerre, J. Thiria, J. S. Dehecq, D. Fontenille, I. Schuffenecker, P. Despres, and A. B. Failloux. 2007. Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus. PLoS One 2:e1168.
81. Walton, T. E., M. M. Jochim, T. L. Barber, and L. H. Thompson. 1989. Cross-protective immunity between equine encephalomyelitis viruses in equids. Am. J. Vet. Res. 50:1442-1446.
82. Wang, E., E. Volkova, A. P. Adams, N. Forrester, S. Y. Xiao, I. Frolov, and S. C. Weaver. 2008. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 26:5030-5039.
83. Wenzel, J., S. Zahn, T. Bieber, and T. Tuting. 2009. Type I interferonassociated cytotoxic inflammation in cutaneous lupus erythematosus. Arch. Dermatol. Res. 301:83-86.
84. Wu, J. Q., N. D. Barabe, Y. M. Huang, G. A. Rayner, M. E. Christopher, and F. L. Schmaltz. 2007. Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 369:206-213.
85. Wust, C. J., R. Crombie, and A. Brown. 1987. Passive protection across subgroups of alphaviruses by hyperimmune non-cross-neutralizing anti-Sindbis serum. Proc. Soc. Exp. Biol. Med. 184:56-63.
86. Xiao, C., Z. I. Rajput, and S. Hu. 2007. Improvement of a commercial foot-and-mouth disease vaccine by supplement of Quil A. Vaccine 25:4795-4800.
87. Yu, S., and J. G. Aaskov. 1994. Development of a candidate vaccine against Ross River virus infection. Vaccine 12:1118-1124.
88. Yun, N. E., B. H. Peng, A. S. Bertke, V. Borisevich, J. K. Smith, J. N. Smith, A. L. Poussard, M. Salazar, B. M. Judy, M. A. Zacks, D. M. Estes, and S. Paessler. 2009. CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus. Vaccine 27:4064-4073.
89. Ziegler, S. A., L. Lu, A. P. da Rosa, S. Y. Xiao, and R. B. Tesh. 2008. An animal model for studying the pathogenesis of chikungunya virus infection. Am. J. Trop. Med. Hyg. 79:133-139.